Sex: U
Vaccine: COVID19
Symptoms: Blood test, Cognitive disorder, Computerised tomogram, Feeling abnormal, Lumbar puncture
Clinical narrative: Cognitive problems (Anaphase, Brian Fog, and memory etc); Brain fog; Tested Positive with PCR test for Covid (Nov 2021); Cognitive problems (Anaphase, Brian Fog, and memory etc. and other health related issues as well) / have deficits; This spontaneous case was reported by a physician and describes the occurrence of COGNITIVE DISORDER (Cognitive problems (Anaphase, Brian Fog, and memory etc. and other health related issues as well) / have deficits), SARS-COV-2 TEST POSITIVE (Tested Positive with PCR test for Covid (Nov 2021)), MEMORY IMPAIRMENT (Cognitive problems (Anaphase, Brian Fog, and memory etc)) and FEELING ABNORMAL (Brain fog) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In February 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, the patient experienced COGNITIVE DISORDER (Cognitive problems (Anaphase, Brian Fog, and memory etc. and other health related issues as well) / have deficits). In November 2021, the patient experienced SARS-COV-2 TEST POSITIVE (Tested Positive with PCR test for Covid (Nov 2021)). On an unknown date, the patient experienced MEMORY IMPAIRMENT (Cognitive problems (Anaphase, Brian Fog, and memory etc)) and FEELING ABNORMAL (Brain fog). At the time of the report, COGNITIVE DISORDER (Cognitive problems (Anaphase, Brian Fog, and memory etc. and other health related issues as well) / have deficits) had not resolved and SARS-COV-2 TEST POSITIVE (Tested Positive with PCR test for Covid (Nov 2021)), MEMORY IMPAIRMENT (Cognitive problems (Anaphase, Brian Fog, and memory etc)) and FEELING ABNORMAL (Brain fog) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2021, SARS-CoV-2 test: positive (Positive) SARS-CoV-2 PCR test positive. On an unknown date, Blood test: results not reported Results not reported. On an unknown date, Computerised tomogram: normal (normal) clear and normal. On an unknown date, Lumbar puncture: normal (normal) Normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Two days after COVID-19 infection patient had same evets which patient experienced after Moderna shot. Patient mentioned events as stroke- like problems.  No concomitant medication was reported by the reporter.  No treatment medication was reported by the reporter.  Company comment:  This case concerns a patient with no relevant medical history who experienced non-serious unexpected AESI of SARS-COV2 test positive, that occurred approximately 9 months after the dose of the mRNA-1273 .  The rechallenge was not applicable due to nature of the event. Based on the current available information, the mRNA-1273 does not contain a virus capable of causing COVID-19 infection after vaccination. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-471202 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 01-Feb-2022: Follow up received contain reporter details, lab data, suspect product start date and event terms updated.; Sender's Comments: This case concerns a patient with no relevant medical history who experienced non-serious unexpected AESI of SARS-COV2 test positive and memory impairment. The memory impairment occurred in the same month after a dose of mRNA-1273 whereas SARS-COV2 test positive  occurred approximately 9 months after the dose of the mRNA-1273 .  The rechallenge was not applicable due to nature of the event of SARS-COV2 test positive  and unspecified dose number. Based on the current available information, the mRNA-1273 does not contain a virus capable of causing COVID-19 infection after vaccination. The benefit-risk relationship of mRNA-1273 is not affected by this report.